Please use this identifier to cite or link to this item:
Title: Successful treatment of recalcitrant discoid lupus erythematosus with ustekinumab.
Filiation: Hospital Universitario de Fuenlabrada
Issue Date: 15-Jan-2017
Citation: Dermatol. Online J..2017 Jan;(23)1:
Abstract: We report a 52-year old woman with a 28-year historyof disfiguring facial discoid lupus erythematosus(DLE), persistent despite both classical therapiesand rituximab. Ustekinumab 45 mg was started incombination with methotrexate and intralesionalcorticosteroids. Methotrexate and intralesionalcorticosteroids were withdrawn 30 months later andustekinumab maintained as monotherapy. Fortyeight months later stable improvement was achievedwithout side effects. Only nine patients with cutaneouslupus erythematosus (CLE) treated with ustekinumabhave been reported to date. Ustekinumab could be apromising alternative in severe and recalcitrant casesof CLE. Possibly, the Th17-inflammation pathway isplaying a role in these patients.
PMID: 28329473
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
eScholarship UC item 206538zm.pdf1.44 MBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons